|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/23/2012 8:04:45 AM
File this under ‘you could see it coming.’ It is no secret on Wall Street that Eli Lilly has its problems. But in case you had tried to overlook the issue, Fitch Rating this morning revised its outlook for the drugmaker to negative from stable. Why? Lilly has the steepest patent cliff in the industry, pressured margins and $4.9 billion in debt. Under the circumstances, one might wonder what took the Fitch analysts so long. In any event, the ratings services offers a few rationales for its move, including patent expirations on products that represent approximately 35 percent of sales for the latest 12-months ending this past June 30. The Zyprexa antipsychotic lost patent protection in 2011. Fitch also anticipates the loss of market protection for the Cymbalta antidepressant and the Humalog insulin will result in sales that will decline at a compound rate of nearly 8 percent between 2012 and 2014, even when including potential commercialization of the growing late-stage R&D pipeline. And the margin pressure from those two losses could jeopardize its ‘A’ Issuer Default Rating which, of course, would hurt its credit rating. Making matters worse, Lilly (LLY) also faces yet another period of key patent expirations in 2017, involving the Alimta cancer treatment, the Strattera ADHD pill and the Cialis sexual dysfunction drug.
|
|
|
|
|
|
|
|
|
|
|